Side-by-side earnings comparison across financial stats, AI summaries, management guidance, risks, quotes, and accountability signals.
HDFC Life reported FY26 PAT of INR 1,910 crore, with VNB growth of 2% to INR 4,034 crore and new business margins of 24.2%, down 140bps YoY due to GST, surrender value changes, and fixed cost absorption.
Read HDFC Life Insurance Company analysis →Star Health delivered a strong operational turnaround in Q4 FY26, with fresh retail growth surging 38% YoY on an N basis and overall GWP reaching ₹6,259 crore (+17% YoY).
Read Star Health analysis →Star Health had the stronger quarter on this simple score because its revenue growth plus EBITDA margin beat HDFC Life Insurance Company. Revenue growth is compared first, with EBITDA margin used as the quality check.
HDFC Life reported FY26 PAT of INR 1,910 crore, with VNB growth of 2% to INR 4,034 crore and new business margins of 24.2%, down 140bps YoY due to GST, surrender value changes, and fixed cost absorption. Individual APE grew 7% YoY, below expectations, as Q4 saw slowdown from unabsorbed GST, softness in bancassurance, and deferment of demand. Retail protection was a bright spot, growing 43% for the year and 46% in Q4, with protection mix expanding to 7.2%. Agency channel grew ahead of the company by 500bps, while partnership channels faced volatility. Management expects margins to improve as GST impact neutralizes by H1 FY27 and growth normalizes. Key risk: competitive intensity in bancassurance, particularly at HDFC Bank, may persist and delay growth recovery.
Star Health delivered a strong operational turnaround in Q4 FY26, with fresh retail growth surging 38% YoY on an N basis and overall GWP reaching ₹6,259 crore (+17% YoY). Underwriting profit jumped 200% YoY to ₹186 crore, driven by a 270bps improvement in combined ratio to 95.7% and a 400bps reduction in loss ratio to 65.2%. The retail loss ratio improved for the third consecutive quarter, aided by disciplined pricing, portfolio recalibration, and enhanced fraud management. However, a ₹558 crore mark-to-market loss from equity market volatility dragged reported PAT to a loss of ₹42 crore. Management guided for sustained loss ratio improvement through continued price hikes and wellness initiatives, targeting a normalized ROE of 13.1%. Key risk: a resurgence in seasonal claims or higher medical inflation could pressure loss ratios.
Retail protection grew 43% in FY26, driven by lower prices post-GST and strengthened product portfolio.
13-month persistency moderated by 200bps during the year, but trends stabilized in Q4.
Agency channel grew 500bps ahead of the company, with strong protection mix and branch expansion.
Annuity mix increased by ~300bps YoY to ~8% of individual APE in Q4, aided by new AGNI product.
Fresh retail premium grew 38% YoY in Q4, driven by both value and volume.
Combined ratio improved to 95.7% from 98.4% in Q4 FY25, reflecting better underwriting.
Retail loss ratio improved 3% YoY to 64.8% in Q4, marking the third consecutive quarterly improvement.
New-to-insurance customers accounted for 94% of fresh premium in Q4, up from 90% last year.
Management expects the GST headwind on margins to taper off and be largely neutralized as the company moves into FY27.
Management guidance marginsThe company aims to deliver VNB growth at least in line with APE growth, with potential for margin expansion as environment stabilizes.
Management guidance growthWith a more favorable yield curve and product refinements, non-par savings are expected to gain share relative to FY26.
Management guidance revenueManagement aims to grow agent count to 1 million within the next two years, adding ~1 lakh agents annually.
Management guidance growthStar Health will maintain its strategy of annual price increases on all products, with no abnormal hikes expected.
Management guidance revenueManagement expects loss ratios to continue improving due to pricing actions, wellness initiatives, and portfolio mix.
Management guidance margins
Aggressive pricing by competitors in the HDFC Bank channel led to market share loss in Q4; if this persists, growth recovery may be delayed.
high · analyst_questionSofter-than-expected top-line growth, particularly in Q4, caused a 90bps drag on margins from fixed cost absorption, which could recur if growth remains weak.
medium · management_commentaryPotential commission caps or IFRS-related adjustments could impact business model and profitability; management acknowledged uncertainty.
medium · analyst_questionA recurrence of vector-borne diseases or higher seasonal claims could pressure loss ratios, as seen in prior years.
medium · analyst_questionRising healthcare costs and claim severity may require higher-than-expected price hikes to maintain margins.
medium · analyst_questionNon-compliance by other insurers with expense of management limits could create competitive distortions, though Star Health is compliant.
low · analyst_question
We are not in a tearing rush to get to that at the cost of growth. Our objective will be to get to fast industry growth and maintain VNB in line with that.
We can easily match this if we want to match it. There's no way we're going to have a lapse-supported product. We are in the business to sell policies, and we are hoping that the customer stays vested in the policy till the very end.
